Insulet Corporation
- Отрасль
- Medical Devices
- Биржа
- США
- Страна / Регион
- USA
- Дата IPO
- 15 мая 2007 г.
- Сотрудники
- 5 400
- Сайт
- www.insulet.com
Сводный диапазон оценки · консервативный $110–$120 / справедливый $120–$160 / оптимистичный $170–$190. При $145.76, В пределах справедливого диапазона внутренней стоимости.
На момент публикации $144.94 (31 мая 2026 г.)
Аналитики по этой бумаге на вашем языке пока нет.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Данные EODHD, показаны в валюте отчётности; только для справки, не является инвестиционной рекомендацией.
История
СкороЭтот раздел заполняется — загляните позже.
Положение в отрасли
СкороЭтот раздел заполняется — загляните позже.